Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 2, 2011, Pages 361-368

  Meijer, Esther ^a   Bakker, Stephan J L ^a   Van Der Jagt, Eric J ^a   Navis, Gerjan ^a   De Jong, Paul E ^a   Struck, Joachim ^b   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BRAHMS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; COPEPTIN; HORMONE PRECURSOR; IODOHIPPURATE SODIUM I 131; IOTALAMIC ACID I 125; UNCLASSIFIED DRUG; UREA; VASOPRESSIN;

ADULT; ALBUMINURIA; ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMA OSMOLARITY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; URINE OSMOLALITY;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; IMMUNOASSAY; IODINE RADIOISOTOPES; IODOHIPPURIC ACID; IOTHALAMIC ACID; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; NETHERLANDS; OSMOLAR CONCENTRATION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RENAL BLOOD FLOW, EFFECTIVE; SEVERITY OF ILLNESS INDEX; URODYNAMICS; VASOPRESSINS;

EID: 79951914154     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04560510     Document Type: Article

References (51)

1. Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 81: 289-298, 1995
2. Peters DJ, Spruit L, Saris JJ, Ravine D, Sandkuijl LA, Fossdal R, Boersma J, van ER, Norby S, Constantinou- Deltas CD: Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 5: 359-362, 1993 (Pubitemid 23351306)
3. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329: 332-342, 1993
4. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007 (Pubitemid 46552051)
5. Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor- mediated effects. Cardiovasc Res 51: 372-390, 2001
6. Grantham JJ: Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: A systems biology approach. Kidney Int 64: 1157-1162, 2003
7. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ: Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66: 964-973, 2004 (Pubitemid 39120999)
8. Wang X, Gattone V, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005 (Pubitemid 41710293)
9. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004 (Pubitemid 38508512)
10. Gattone VH, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003 (Pubitemid 37279858)
11. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006 (Pubitemid 44141912)
12. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB: Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 5: I129-I138, 1983
13. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112-119, 2006 (Pubitemid 43032474)
14. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, Keller U, Christ-Crain M: Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 92: 3973-3978, 2007 (Pubitemid 47607649)
15. Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 19: 43-49, 2008 (Pubitemid 351317895)
16. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343: 824-827, 1994 (Pubitemid 24147512)
17. Moore DS, McCabe GP: Introduction to the Practice of Statistics, 4th ed, New York, W.H. Freeman, 2002
18. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B: Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 94: 123-129, 2009
19. Donker AJ, van der Hem GK, Sluiter WJ, Beekhuis H: A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 20: 97-103, 1977 (Pubitemid 8129523)
20. Apperloo AJ, de Zeeuw D, Donker AJ, de Jong PE: Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. J Am Soc Nephrol 7: 567-572, 1996 (Pubitemid 126427122)
21. Zietse R, Blankestijn PJ, Pos B, Balk AH, Derkx FH, Weimar W, Schalekamp MA: Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model. Clin Nephrol 43: 29-34, 1995
22. Michels WM, Grootendorst DC, Rozemeijer K, Dekker FW, Krediet RT: Glomerular filtration rate measurements by (125)I-iothalamate should be corrected for inaccurate urine collections with (131)I-hippuran. Clin Nephrol 72: 337-343, 2009
23. Bae KT, Commean PK, Lee J: Volumetric measurement of renal cysts and parenchyma using MRI: Phantoms and patients with polycystic kidney disease. J Comput Assisted Tomogr 24: 614-619, 2000 (Pubitemid 32204335)
24. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, Jr., Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006 (Pubitemid 43736612)
25. Grantham JJ, Chapman AB, Torres VE: Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol 1: 148-157, 2006
26. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP: Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2: 112-120, 2007
27. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64: 1035-1045, 2003 (Pubitemid 37013840)
28. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 1349-1354, 1994 (Pubitemid 24977120)
29. Michalski A, Grzeszczak W: [The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease]. Pol Arch Med Wewn 96: 329-343, 1996
30. Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Kornerup HJ, Posborg V: Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 219: 399-405, 1986 (Pubitemid 16052291)
31. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 77: 29-36, 2010
32. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88: 561-567, 2009
33. Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35: 675-680, 1989 (Pubitemid 19051769)
34. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ: Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003
35. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008
36. Gretz N, Zeier M, Geberth S, Strauch M, Ritz E: Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease. Am J Kidney Dis 14: 178-183, 1989 (Pubitemid 19241463)
37. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41: 1311-1319, 1992
38. Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grunfeld JP, Jungers P: Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6: 1634-1642, 1995 (Pubitemid 26184577)
39. Bouby N, Ahloulay M, Nsegbe E, Dechaux M, Schmitt F, Bankir L: Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 7: 842-851, 1996 (Pubitemid 27465977)
40. Naito A, Hasegawa H, Kurasawa T, Ohtake Y, Matsukawa H, Ezure Y, Koike K, Shigenobu K: Histopathological study of kidney abnormalities in an experimental SIADH rat model and its application to the evaluation of the pharmacologic profile of VP-343, a selective vasopressin V2 receptor antagonist. Biol Pharm Bull 24: 897-901, 2001 (Pubitemid 32750314)
41. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, Bankir L: Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 18: 497-506, 2003 (Pubitemid 36305653)
42. Bouby N, Bachmann S, Bichet D, Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258: F973-F979, 1990 (Pubitemid 20155510)
43. Bouby N, Hassler C, Bankir L: Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats. Life Sci 65: 991-1004, 1999 (Pubitemid 29410384)
44. Bankir, Trinh-Trang-Tan MM: Urea and the kidney. In: The Kidney, 6th ed., edited by Brenner BM, Philadelphia, W.B. Saunders, 2000: 637-679.
45. Okada H, Suzuki H, Kanno Y, Yamamura Y, Saruta T: Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Clin Sci (Lond) 86: 399-404, 1994
46. Sugiura T, Yamauchi A, Kitamura H, Matsuoka Y, Horio M, Imai E, Hori M: High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: Possible role of TGF-beta. Kidney Int 55: 1800-1810, 1999
47. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL: Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116: 257-263, 2009
48. Baumann G, Dingman JF: Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 57: 1109-1116, 1976
49. Garcia Nieto VM, Yanes MI, Zamorano MM, Gonzalez MJ, Aros CP, Garin EH: Renal concentrating capacity as a marker for glomerular filtration rate. Acta Paediatr 97: 96-99, 2008
50. Tannen RL, Regal EM, Dunn MJ, Schrier RW: Vasopressin- resistant hyposthenuria in advanced chronic renal disease. N Engl J Med 280: 1135-1141, 1969
51. Meijer E, Rook M, Tent H, Navis G, Jagt EJ, Jong PE, Gansevoort RT: Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5: 1091-1098, 2010